CONDENSED CONSOLIDATED STATEMENTS OF LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues [Abstract]
Product sales	$ 0	$ 12,243
Operating expenses:
Cost of products	0	2,457
Research and development expenses	3,852	5,530
Selling, general and administrative expenses	11,012	7,913
Intangible asset amortization	0	203
Changes in fair value of contingent consideration	0	2,478
Restructuring (income) costs	(53)	159
Total operating expense	14,811	18,740
Operating loss	(14,811)	(6,497)
Investment and other income (expense), net	610	(378)
Interest expense	(1,929)	(3,190)
Gain from release of certain liabilities	78	0
Other expense - changes in fair value of contingent consideration payable	0	(310)
Loss before income taxes	(16,052)	(10,375)
Income tax benefit	(2,607)	(9,510)
Net loss	$ (13,445)	$ (865)
Net loss per share - basic (in dollars per share)	$ (0.23)	$ (0.02)
Net loss per share - diluted (in dollars per share)	$ (0.23)	$ (0.02)
Weighted average number of shares outstanding - basic (in shares)	58,443	41,057
Weighted average number of shares outstanding - diluted (in shares)	58,443	41,057